Literature DB >> 2032890

Three-dimensional treatment planning for lung cancer.

B Emami1, J A Purdy, J Manolis, G Barest, E Cheng, L Coia, K Doppke, J Galvin, T LoSasso, J Matthews.   

Abstract

The experience of four institutions involved in a three-dimensional treatment planning contract (NCI) for lung cancer is described. It was found that three-dimensional treatment planning has a significant potential for optimization of treatment plans for radiotherapy of lung cancer both for tumor coverage and sparing of critical normal tissues within the complex anatomy of the human thorax. Evaluation tools, such as dose-volume histograms, and three-dimensional isodose displays, such as multiple plane views, surface dose displays, etc., were found to be extremely valuable in evaluation and comparison of these complex plans. It is anticipated that with further developments in three-dimensional simulation and treatment delivery systems, major progress towards uncomplicated local regional control of lung cancer may be forthcoming.

Entities:  

Mesh：

Year:  1991        PMID： 2032890     DOI： 10.1016/0360-3016(91)90180-c

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN： 0360-3016            Impact factor:   7.038


  7 in total

1.  [Pneumonitis after radiotherapy of bronchial carcinoma: incidence and influencing factors].

Authors:  P Schraube; R Schell; M Wannenmacher; P Drings; M Flentje
Journal:  Strahlenther Onkol       Date:  1997-07       Impact factor: 3.621

2.  Conformal radiotherapy for lung cancer: interobservers' variability in the definition of gross tumor volume between radiologists and radiotherapists.

Authors:  Chiang J Tyng; Rubens Chojniak; Paula N V Pinto; Marcelle A Borba; Almir G V Bitencourt; Ricardo C Fogaroli; Douglas G Castro; Paulo E Novaes
Journal:  Radiat Oncol       Date:  2009-08-05       Impact factor: 3.481

3.  Patterns of Treatment and Outcomes for Definitive Therapy of Early Stage Non-Small Cell Lung Cancer.

Authors:  Nirav S Kapadia; Luca F Valle; Julie A George; Reshma Jagsi; Thomas A D'Amico; Elisabeth U Dexter; Fawn D Vigneau; Feng Ming Kong
Journal:  Ann Thorac Surg       Date:  2017-10-26       Impact factor: 4.330

4.  177Lu-PSMA-617 Therapy in Mice, with or without the Antioxidant α1-Microglobulin (A1M), Including Kidney Damage Assessment Using 99mTc-MAG3 Imaging.

Authors:  Amanda Kristiansson; Anders Örbom; Jonas Ahlstedt; Helena Karlsson; Wahed Zedan; Magnus Gram; Bo Åkerström; Sven-Erik Strand; Mohamed Altai; Joanna Strand; Oskar Vilhelmsson Timmermand
Journal:  Biomolecules       Date:  2021-02-10

5.  Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate.

Authors:  Hendrik Bergsma; Mark W Konijnenberg; Wouter A van der Zwan; Boen L R Kam; Jaap J M Teunissen; Peter P Kooij; Katya A L Mauff; Eric P Krenning; Dik J Kwekkeboom
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-05-10       Impact factor: 9.236

6.  Reducing the number of CTs performed to monitor personalized dosimetry during peptide receptor radionuclide therapy (PRRT).

Authors:  Alexandre Chicheportiche; Faozi Artoul; Arnon Schwartz; Simona Grozinsky-Glasberg; Amichay Meirovitz; David J Gross; Jeremy Godefroy
Journal:  EJNMMI Phys       Date:  2018-06-19

Review 7.  Cardiovascular Damage Associated With Chest Irradiation.

Authors:  Simone M Mrotzek; Tienush Rassaf; Matthias Totzeck
Journal:  Front Cardiovasc Med       Date:  2020-03-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.